| Name | Title | Contact Details |
|---|
Our story begins in 2005, with a healthcare professional, Dr. Kathleen Myers. She was hired to help open a new, paperless hospital using multiple EMRs and CPOE. A dedicated emergency medicine physician, she knew that every minute counted and worried that “going paperless” would take valuable time away from patients — which was unacceptable. She challenged herself to find a solution. Her answer was a scribe program. She championed development of this for her emergency department, and scribes quickly became an indispensable part of her practice of medicine. So much so, that Dr. Myers sought the support of like-minded individuals with an entrepreneurial spirit to bring these services to other physicians across the country. This is where the company took root. In 2011, Dr. Myers founded Essia Health (formerly Scribes STAT, Inc.) in Portland, Oregon. As a physician, Dr. Myers’ deep expertise helped her to find the pain points of medical practice —where Essia could be most impactful: premium scribe services and EMR support for healthcare providers. In 2013 she was joined by a leadership team of industry experts to carry out Essia’s mission. The response was tremendous. Today, Essia Health has more than 600 employees partnering with institutions nationwide to empower physicians to focus on the practice of medicine. Recognized as a premier provider of scribe services and EMR support, Essia has won multiple awards for excellence in client satisfaction. We have partnered with multi-state hospital networks, specialty clinics, and multispecialty clinics, and we have managed more than 200 successful EMR Go-Lives. Technological change is important. People are most important. Which is why Essia is proud of a heritage of best-in-class service to help our customers navigate this change effectively. We do this by anticipating and resolving unique challenges with quick, innovative solutions that make technology work for you — and not the other way around! There’s nothing better than working with people who truly speak your language.
American Pathology Partners (AP2) company career center! We appreciate your interest in career opportunities with us and encourage you to explore our site to learn more about us and our partner laboratories in Colorado (UniPath), Florida (Palm Beach Pathology), North Carolina (Eastern Carolina Pathology). We are committed to building long-term partnerships within the communities we serve through service excellence and our commitment to the latest in technological innovation. Our pathologist partners are valued leaders within our affiliated laboratories and deliver specialized anatomic and molecular pathology services within their local and regional healthcare markets. As a growing organization, we offer a diversity of laboratory positions in histology, grossing, flow cytometry, cytology processing, molecular as well as career opportunities in finance, sales, information technology and human resources. We offer a competitive salary and excellent benefits package including Medical, Dental, Vision, Life, Long-Term Disability, Flexible Spending Accounts, and a Tuition Reimbursement Program. In addition, we support ongoing educational programs and career opportunities; provide liberal Paid Time Off benefits; and offer a generous Retirement 401(k) plan.
MedSource Consulting is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RMI Physician Services is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.